Transdermal therapeutic system TTS containing tolterodine
AssigneeSchwarz Pharma AG
InventorsChristoph Arth, Claus Meese, Dietrich Wilhelm Schacht, Hans-Michael Wolff
Life of this patent
Estimating the term…
Abstract
The invention relates to a transdermal therapeutic system (TTS) for transcutaneously administering tolterodine over a period of several days and to a method for producing the same. The TTS contains a self-adhesive layer-shaped matrix composition which contains a (meth)acrylate copolymer comprising ammonium groups. The TTS also contains at least one plasticizer and up to 25 wt, % of tolterodine.
Claims7
A transdermal therapeutic system (TTS) for transcutaneous administration of tolterodine over a period of up to seven days, wherein the system comprises a layer of a tolterodine containing a matrix composition disposed on a carrier film, said matrix composition comprising a solid solution of (a) a copolymer of ethyl acrylate and methyl methacrylate containing about 5% trimethylammonium ethyl methacrylate chloride as the sole (meth)acrylate copolymer, (b) at least one plasticizer and (c) up to 25 weight percent of tolterodine, and wherein the system is free of an adhesive layer.
A transdermal therapeutic system for the transcutaneous administration of tolterodine over a period of up to seven days, wherein the system comprises a layer form of a tolterodine-containing matrix composition disposed on a carrier film, said matrix composition comprising (a) a copolymer of ethyl acrylate and methyl methacrylate containing about 5% trimethylammonium ethyl methacrylate chloride as the sole (meth)acrylate copolymer, (b) at least one plasticizer, and (c) up to 25 weight percent of tolterodine, and that said matrix composition, with the exception of its release surface, is surrounded by a larger patch, which is free from active ingredient, for fixing to skin at the point of application.
Dependencies are inferred from the claim text.